First patient dosed in Nacuity’s Phase III Usher syndrome RP trial
Nacuity Pharmaceuticals has dosed the first patient in its global confirmatory Phase III SLO-RP Preserve study evaluating NPI-001 for RP associated with Usher syndrome.
The post First patient dosed in Nacuity’s Phase III Usher syndrome RP trial appeared first on Clinical Trials Arena .